S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
NASDAQ:ARWR

Arrowhead Pharmaceuticals - ARWR Stock Forecast, Price & News

$42.61
-1.40 (-3.18%)
(As of 08/19/2022 04:17 PM ET)
Add
Compare
Today's Range
$42.14
$44.03
50-Day Range
$27.79
$48.31
52-Week Range
$26.81
$84.83
Volume
555,418 shs
Average Volume
781,844 shs
Market Capitalization
$4.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.83

Arrowhead Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
67.6% Upside
$70.83 Price Target
Short Interest
Healthy
4.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.57
Upright™ Environmental Score
News Sentiment
-0.04mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.08) to ($1.47) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

700th out of 1,119 stocks

Pharmaceutical Preparations Industry

341st out of 549 stocks

ARWR stock logo

About Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ARWR. HC Wainwright reissued a "buy" rating and set a $110.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 14th. Piper Sandler cut their target price on Arrowhead Pharmaceuticals from $89.00 to $72.00 in a research report on Wednesday, May 11th. Chardan Capital raised their price target on Arrowhead Pharmaceuticals from $80.00 to $82.00 in a research report on Friday, August 5th. Robert W. Baird upgraded shares of Arrowhead Pharmaceuticals from a "neutral" rating to an "outperform" rating and cut their price objective for the company from $71.00 to $60.00 in a research report on Wednesday, May 11th. Finally, The Goldman Sachs Group increased their target price on shares of Arrowhead Pharmaceuticals from $58.00 to $65.00 and gave the company a "buy" rating in a research note on Monday, August 8th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $70.83.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock traded down $0.66 during mid-day trading on Friday, hitting $43.35. The company's stock had a trading volume of 1,229 shares, compared to its average volume of 697,884. Arrowhead Pharmaceuticals has a one year low of $26.81 and a one year high of $84.83. The company has a 50 day moving average of $39.61 and a 200-day moving average of $41.60. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.37 and a current ratio of 3.37.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.17). Arrowhead Pharmaceuticals had a negative return on equity of 36.05% and a negative net margin of 61.58%. The company had revenue of $32.41 million during the quarter, compared to the consensus estimate of $52.61 million. During the same quarter in the previous year, the company posted ($0.29) earnings per share. The company's revenue for the quarter was down 29.4% on a year-over-year basis. On average, sell-side analysts forecast that Arrowhead Pharmaceuticals will post -1.08 earnings per share for the current year.

Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Stock News Headlines

The Coming Copper Bull Run
Copper prices have nearly doubled since last year -- driven by the explosive growth in electric vehicles and soaring demand for green-powered electricity. But copper demand far outpaces supply. Multinational investment banks are predicting a 50% to 100% rise in copper prices by 2025. And this "backdoor" play may be a move to consider.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 7%
The Coming Copper Bull Run
Copper prices have nearly doubled since last year -- driven by the explosive growth in electric vehicles and soaring demand for green-powered electricity. But copper demand far outpaces supply. Multinational investment banks are predicting a 50% to 100% rise in copper prices by 2025. And this "backdoor" play may be a move to consider.
5 Top Biotech Stocks To Watch In July 2022
See More Headlines
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Company Calendar

Last Earnings
8/04/2022
Today
8/19/2022
Fiscal Year End
9/30/2022
Next Earnings (Estimated)
11/28/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARWR
Employees
329
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$70.83
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+66.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-140,850,000.00
Pretax Margin
-61.58%

Debt

Sales & Book Value

Annual Sales
$138.29 million
Book Value
$4.48 per share

Miscellaneous

Free Float
102,144,000
Market Cap
$4.51 billion
Optionable
Optionable
Beta
1.37

Key Executives

  • Dr. Christopher R. Anzalone Ph.D. (Age 53)
    CEO, Pres & Director
    Comp: $1.68M
  • Mr. Kenneth A. MyszkowskiMr. Kenneth A. Myszkowski (Age 56)
    Chief Financial Officer
    Comp: $729.77k
  • Mr. Patrick O'Brien (Age 58)
    Chief Compliance Officer, Gen. Counsel & Corp. Sec.
    Comp: $733.13k
  • Dr. James C. Hamilton M.D. (Age 43)
    MBA, Sr. VP of Discovery & Translational Medicine
    Comp: $673.45k
  • Dr. Javier San Martin M.D. (Age 57)
    Chief Medical Officer
    Comp: $658.48k
  • Dr. Mark M. Davis Ph.D.
    Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Ms. Jane Davidson
    Head of HR & Admin., VP and Corp. Sec.
  • Dr. Vincent Anzalone CFA
    Head of Investor Relations & VP
  • Mr. Howard Lovy
    Director of Communications
  • Dr. Mark Seefeld (Age 68)
    Head of Toxicology & VP













ARWR Stock - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARWR shares.
View ARWR analyst ratings
or view top-rated stocks.

What is Arrowhead Pharmaceuticals' stock price forecast for 2022?

5 brokerages have issued 1 year price targets for Arrowhead Pharmaceuticals' shares. Their ARWR share price forecasts range from $36.00 to $110.00. On average, they expect the company's share price to reach $70.83 in the next twelve months. This suggests a possible upside of 60.9% from the stock's current price.
View analysts price targets for ARWR
or view top-rated stocks among Wall Street analysts.

How have ARWR shares performed in 2022?

Arrowhead Pharmaceuticals' stock was trading at $66.30 on January 1st, 2022. Since then, ARWR shares have decreased by 33.6% and is now trading at $44.01.
View the best growth stocks for 2022 here
.

When is Arrowhead Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 28th 2022.
View our ARWR earnings forecast
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.17. The biotechnology company had revenue of $32.41 million for the quarter, compared to the consensus estimate of $52.61 million. Arrowhead Pharmaceuticals had a negative net margin of 61.58% and a negative trailing twelve-month return on equity of 36.05%. Arrowhead Pharmaceuticals's revenue was down 29.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.29) earnings per share.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (5.27%), JPMorgan Chase & Co. (2.83%), FMR LLC (2.59%), Northern Trust Corp (1.22%), Credit Suisse AG (1.21%) and Fiera Capital Corp (1.06%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Michael S Perry, Patrick O'brien and William D Waddill.
View institutional ownership trends
.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $44.01.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $4.66 billion and generates $138.29 million in revenue each year. The biotechnology company earns $-140,850,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

The company employs 329 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401.

This page (NASDAQ:ARWR) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.